The FDA has approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.Zidesamtinib (Jideytro, GSK) is designed to provide highly selective coverage ...

GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.

GSK plc GSK announced that the FDA has approved Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer (NSCLC). Jideytro was added as a late-stage candidate to GSK’s ...

In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the first ...

Non–small cell lung cancer (NSCLC), a malignancy that forms in the tissues of the lungs, accounts for the majority of lung ...

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ...

Summit Therapeutics SMMT announced updated overall survival ("OS") data from the phase III HARMONi study evaluating its investigational antibody ivonescimab in certain patients with non-small cell ...

Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Your treatment journey for non-small-cell lung cancer (NSCLC) may vary from that of others with the same diagnosis. But you’ll likely start with some of the same treatments. You’ll have lots of ...

A diagnosis of non-small cell lung cancer (NSCLC) can significantly affect emotional health, leading to mental health challenges such as depression, anxiety, and distress. Comprehensive mental health ...